Anti-L1CAM antibody: A novel efficacious immunotherapy for pancreatic and ovarian cancer patients

Project Information

Anti-L1CAM

Grant agreement ID: 858753

DOI 10.3030/858753

Project terminated on 10 March 2023

EC signature date 4 June 2019

Start date 1 September 2019

End date 29 February 2024

Funded under

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Total cost € 4 251 412,50

EU contribution € 2 495 176,25

Coordinated by

ELTHERA AG
Switzerland

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Publications

Peer reviewed articles (1)

LCB97, an antibody drug conjugate (ADC) targeting a novel tumor antigen for the treatment of multiple solid tumors

Author(s): Yeojin Jeong, Gunther Spohn, Flavio Mehli, Chul-Woong Chung, Changsik Park
Published in: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5653, 2023, ISSN 0008-5472
Publisher: American Association for Cancer Research
DOI: 10.1158/1538-7445.am2023-5653